Latest Digestive diseases Stories
When laboratory mice were modeled with colitis and treated with human umbilical cord-derived mesenchymal cells, the cells homed in on the inflamed colon and effectively ameliorated colitis, reported a study published in a recent issue of Cell Transplantation (20:9), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/. According to study corresponding author Dr. Zhong Chao Han of the Institute of Hematology, Chinese Academy of Sciences and Peking Union of Medical...
A large-scale study of medical claims data shows that introducing sophisticated biologic therapies early in the course of treatment for Crohn's disease improves response to medication and reduces the need for surgery. There is no known cure for Crohn's disease, and traditional treatment is focused on a "step-up" strategy of managing inflammatory symptoms, starting with simpler and less costly oral medications such as aminosalicylates (5-ASAs) and corticosteroids, and escalating through a...
Premier fund-raising event for the Chapter, benefiting Crohn’s disease and ulcerative colitis patients and their families Philadelphia, PA (PRWEB) April 09, 2012 On Saturday, April 21, 2012, the Philadelphia/Delaware Valley Chapter of the Crohn’s & Colitis Foundation of America (CCFA) will host its 37th annual Got Guts Gala at the Simeone Foundation Automotive Museum in Philadelphia, Pa. This affair is the premier fund-raising event for the Chapter, benefiting Crohn’s disease...
Researchers at the University of Central Florida have developed a novel technique that may give doctors a faster and more sensitive tool to detect pathogens associated with inflammatory bowel disease, including Crohn's disease. The new nanoparticle-based technique also may be used for detection of other microbes that have challenged scientists for centuries because they hide deep in human tissue and are able to reprogram cells to successfully evade the immune system. The microbes...
PHILADELPHIA, Pennsylvania, March 30, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced top-line results of the PREVENT2 trial, a phase 3 investigational study of once-daily SPD476, MMX(R) mesalamine in patients with a history of diverticulitis.[1] The study, conducted in 10 countries worldwide including the United States, did not meet the primary endpoint in reducing the rate of recurrence of...
Calendar Announcement/ Event Listing; Attention: Society/Event Editors Philadelphia, PA (PRWEB) March 28, 2012 The Philadelphia/Delaware Valley Chapter of the Crohn’s & Colitis Foundation of America will host its 37th annual Got Guts Gala on Saturday, April 21, 2012 at 7 p.m. This is the premier fund-raising event for the Chapter, benefiting Crohn’s disease and ulcerative colitis patients and their families. The Gala is an opportunity for the Chapter to recognize individuals for...
Researchers from the Hotchkiss Brain Institute (HBI) and the Snyder Institute for Chronic Diseases at the University of Calgary's Faculty of Medicine have discovered a pathway that may contribute to the symptoms related to Crohn's disease and ulcerative colitis, collectively known as Inflammatory Bowel Disease (IBD). This research is a major milestone in developing future drug therapies for those living with these debilitating disorders. The digestive process is complex. To coordinate the...
Despite advances in neonatal care, necrotizing enterocolitis (NEC) – the most common gastrointestinal emergency in premature infants – continues to be a deadly disease. “We haven’t made a lot of progress in identifying babies early who may be at risk for NEC, preventing it or treating it,” said Jörn-Hendrik Weitkamp, M.D., a neonatologist and assistant professor of Pediatrics at Monroe Carell Jr. Children's Hospital at Vanderbilt. Now, Weitkamp and his colleagues have...
The Nutritional Immunology and Molecular Medicine Laboratory (NIMML) research team at Virginia Tech has discovered important new information on the efficacy of conjugated linoleic acid (CLA) in treating Crohn’s disease, a form of inflammatory bowel disease (IBD). CLA is a naturally occurring acid found in meat and dairy products known for its anti-cancer and immune modulatory properties. In collaboration with the Division of Gastroenterology and Hepathology at University of North...
LEXINGTON, Mass., March 19, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease. Avaxia Biologics has been awarded a Phase II Small Business Innovation Research (SBIR) grant...
